Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target

Marieke L Kuijjer, Brendy E W M van den Akker, Riet Hilhorst

  • 1Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2300RC Leiden, The Netherlands. a.m.cleton-jansen@lumc.nl.

BMC Medical Genomics
|January 23, 2014
PubMed
Abstract

Insights

High-grade osteosarcoma pathways involved in genomic stability are deregulated. Akt signaling inhibition shows promise for treating some osteosarcoma cases, warranting further investigation.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • High-grade osteosarcoma (HGO) is a primary bone cancer with limited survival improvement since the 1970s.
  • The complex and heterogeneous genomic profile of HGO necessitates integrated data analysis for better understanding.
  • Understanding genomic aberrations is crucial for developing effective HGO treatments.

Purpose of the Study:

  • To investigate deregulated pathways in high-grade osteosarcoma using genome-wide data.
  • To identify potential therapeutic targets by analyzing gene expression and kinome screening data.
  • To evaluate the efficacy of inhibiting specific signaling pathways in osteosarcoma cell lines.

Main Methods:

  • Genome-wide gene expression data and kinome screening data were analyzed.
  • Statistical analysis using R and LIMMA identified differentially expressed and phosphorylated genes.
  • Ingenuity Pathways Analysis (IPA) was employed to determine deregulated pathways.

Main Results:

  • Pathways crucial for genomic stability were found to be highly deregulated in HGO.
  • Akt signaling was identified as active, while AMPK signaling was inactive, impacting mTORC1.
  • Inhibition of Akt kinases with MK-2206 reduced proliferation in 2/3 osteosarcoma cell lines tested.

Conclusions:

  • Overexpression and hyperphosphorylation in genomic stability pathways were observed in HGO.
  • Active Akt signaling presents a potential therapeutic target for a subset of osteosarcoma patients.
  • Targeting the PI3K/Akt/mTORC1 pathway may be effective, but requires further validation in diverse osteosarcoma subgroups.